Document Detail

A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease.
MedLine Citation:
PMID:  20398713     Owner:  NLM     Status:  MEDLINE    
Alzheimer's disease is the most common neurodegenerative disease of the central nervous system characterized by a progressive loss in memory and deterioration of cognitive functions. In this study the transgenic mouse TgCRND8, which encodes a mutant form of the amyloid precursor protein 695 with both the Swedish and Indiana mutations and develops extracellular amyloid beta-peptide deposits as early as 2-3 months, was investigated. Extract from eight brain regions (cortex, frontal cortex, cerebellum, hippocampus, olfactory bulb, pons, midbrain and striatum) were studied using (1)H NMR spectroscopy. Analysis of the NMR spectra discriminated control from APP695 tissues in hippocampus, cortex, frontal cortex, midbrain and cerebellum, with hippocampal and cortical region being most affected. The analysis of the corresponding loading plots for these brain regions indicated a decrease in N-acetyl-L-aspartate, glutamate, glutamine, taurine (exception hippocampus), gamma-amino butyric acid, choline and phosphocholine (combined resonances), creatine, phosphocreatine and succinate in hippocampus, cortex, frontal cortex (exception gamma-amino butyric acid) and midbrain of affected animals. An increase in lactate, aspartate, glycine (except in midbrain) and other amino acids including alanine (exception frontal cortex), leucine, iso-leucine, valine and water soluble free fatty acids (0.8-0.9 and 1.2-1.3 ppm) were observed in the TgCRND8 mice. Our findings demonstrate that the perturbations in metabolism are more widespread and include the cerebellum and midbrain. Furthermore, metabolic perturbations are associated with a wide range of metabolites which could improve the diagnosis and monitoring of the progression of Alzheimer's disease.
Reza M Salek; Jing Xia; Amy Innes; Brian C Sweatman; Robert Adalbert; Suzanne Randle; Eileen McGowan; Piers C Emson; Julian L Griffin
Related Documents :
10837313 - Can nutrient supplements modify brain function?
1693553 - Anticonvulsant activity of di-n-propylacetate and brain monoamine metabolism in the rat.
8112253 - Pharmacokinetics and pharmacodynamics of valproate analogues in rats. iv. anticonvulsan...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-04-14
Journal Detail:
Title:  Neurochemistry international     Volume:  56     ISSN:  1872-9754     ISO Abbreviation:  Neurochem. Int.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-05-18     Completed Date:  2010-11-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006959     Medline TA:  Neurochem Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  937-47     Citation Subset:  IM    
Copyright Information:
2010 Elsevier Ltd. All rights reserved.
Department of Biochemistry, The Hopkins Building, Tennis Court Road, University of Cambridge, Cambridge CB21QW, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alzheimer Disease / diagnosis,  metabolism*,  pathology*
Biological Markers / metabolism
Brain / metabolism,  pathology
Disease Models, Animal*
Metabolome / genetics
Metabolomics / methods*
Mice, Transgenic
Grant Support
R01AG020216-01A2/AG/NIA NIH HHS; R21 DK070288-01/DK/NIDDK NIH HHS
Reg. No./Substance:
0/Biological Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cell delivery therapeutics for musculoskeletal regeneration.
Next Document:  Diabetes synergistically exacerbates poststroke dementia and tau abnormality in brain.